Upsher-Smith Laboratories announced the launch of Doxazosin Tablets, USP, 1 mg, 2 mg, 4 mg, and 8 mg. The product was approved by the FDA on April 17, 2018. Upsher-Smith’s Doxazosin Tablets are an AB-rated generic version of the branded product, Cardura (doxazosin mesylate tablets).
The doxazosin tablet market had U.S. sales of approximately $51.2 millionfor the 12 months ending January, 2018 according to IQVIA.
(Source: Upsher-Smith Laboratories, LLC)
Filed Under: Drug Discovery